Chorostowska-Wynimko Joanna, Swiercz Rafal, Skrzypczak-Jankun Ewa, Selman Steven H, Jankun Jerzy
Department of Laboratory Diagnostics and Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
Oncol Rep. 2004 Dec;12(6):1155-62.
Plasminogen activator inhibitor type-1 (PAI-1) is considered one of the key regulators of tumor invasion, metastasis, as well as cancer-related angiogenesis. The literature suggests that PAI-1 plays a dual role in these processes because it inhibits plasmin-originated proteolysis and binds to vitronectin or integrins. Stimulation or inhibition of angiogenesis largely depends on which of these elements PAI-1 interacts. Wild PAI-1 converts quickly into its latent, inactive form and loses its anti-proteolytic activity, but still binds to vitronectin and integrins. Thus we constructed PAI-1s with extended half-life to prolong their anti-proteolytic activity. We have analyzed the effects of sprout formation inhibition by PAI-1s on two functionally different endothelial cell (EC) systems, human umbilical vein endothelial cells (HUVEC), expressing moderate amounts of urokinase (uPA), and human lung microvascular endothelial cells (HLMVEC), expressing high amounts of this enzyme. We have used wild-type PAI-1 (wPAI-1) (t(1/2) = 1.6 h) and PAI-1 cysteine mutants (CysPAI-1) characterized by their prolonged half-life time (hDbetaT) (t(1/2) = 63.6 h and t(1/2) = 7,000 h). We have observed a significant inhibitory dose-dependent effect exerted by the CysPAI-1s on sprout formation by HUVEC and HLMVEC cells. The inhibition rate was considerably stronger in lung capillary cell cultures and significantly more pronounced for CysPAI-1 mutants with longer anti-uPA activity (betaT). wPAI-1 with a short anti-proteolytic half-life has induced sprout formation in HUVEC, but not in HLMVEC cultures. This difference in behavior was most likely related to the presence of excessive amounts of uPA in HLMVEC cells and the known mechanism of clearing PAI-1/uPA/uPAR complexes from the cell surface. A less efficient system of HUVEC cells might give wPAI-1 the chance to interact with non-proteolytic pathways of angiogenesis stimulation. We conclude that while the anti-proteolytic properties of PAI-1 constructs are preserved, these proteins inhibit angiogenesis and inhibitory activity dominates over any stimulatory effects of PAI-1.
纤溶酶原激活物抑制剂 -1(PAI-1)被认为是肿瘤侵袭、转移以及癌症相关血管生成的关键调节因子之一。文献表明,PAI-1在这些过程中发挥双重作用,因为它抑制纤溶酶介导的蛋白水解作用,并与玻连蛋白或整合素结合。血管生成的刺激或抑制很大程度上取决于PAI-1与这些成分中的哪一种相互作用。野生型PAI-1会迅速转化为其潜伏的无活性形式,并失去其抗蛋白水解活性,但仍能与玻连蛋白和整合素结合。因此,我们构建了半衰期延长的PAI-1,以延长其抗蛋白水解活性。我们分析了PAI-1对两种功能不同的内皮细胞(EC)系统(表达适量尿激酶(uPA)的人脐静脉内皮细胞(HUVEC)和表达大量该酶的人肺微血管内皮细胞(HLMVEC))芽生形成的抑制作用。我们使用了野生型PAI-1(wPAI-1)(半衰期(t(1/2)=1.6)小时)和具有延长半衰期(hDbetaT)(半衰期(t(1/2)=63.6)小时和(t(1/2)=7000)小时)的PAI-1半胱氨酸突变体(CysPAI-1)。我们观察到CysPAI-1对HUVEC和HLMVEC细胞的芽生形成具有显著的抑制剂量依赖性效应。在肺毛细血管细胞培养物中,抑制率更强,对于具有更长抗uPA活性(betaT)的CysPAI-1突变体,抑制作用明显更显著。具有短抗蛋白水解半衰期的wPAI-1在HUVEC中诱导了芽生形成,但在HLMVEC培养物中未诱导。这种行为差异很可能与HLMVEC细胞中存在过量的uPA以及从细胞表面清除PAI-1/uPA/uPAR复合物的已知机制有关。HUVEC细胞中效率较低的系统可能使wPAI-1有机会与血管生成刺激的非蛋白水解途径相互作用。我们得出结论,虽然PAI-1构建体的抗蛋白水解特性得以保留,但这些蛋白质会抑制血管生成,且抑制活性超过PAI-1的任何刺激作用。